kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”kpccz-1679Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ. Кардиология. Патологическая физиологияORIGINAL STUDIES. Cardiology. Pathlogical physiologyХОЛЕСТЕРИНОВАЯ АТЕРОЭМБОЛИЯ КАК ПРИЧИНА НАРУШЕНИЯ РЕПЕРФУЗИИ МИОКАРДА ПРИ ЭНДОВАСКУЛЯРНОМ ВОССТАНОВЛЕНИИ КОРОНАРНОГО КРОВОТОКА (ОБЗОР ЛИТЕРАТУРЫ)https://orcid.org/0000-0003-2197-8756СуковатыхБорис СеменовичSukovatykhBS@kursksmu.nethttps://orcid.org/0000-0003-0590-2225БоломатовНиколай ВладимировичSukovatykhBS@kursksmu.nethttps://orcid.org/0000-0001-8964-5937СидоровДмитрий ВладимировичD7600S@yandex.ruhttps://orcid.org/0000-0003-1907-4395СуковатыхМихаил БорисовичSukovatykhMB@kursksmu.nethttps://orcid.org/0000-0002-5039-5384ГригорьянАрсен Юрьевич

кафедра оперативной хирургии и топографической анатомии

SPIN-код: 3090-4890

arsgrigorian@mail.ruhttps://orcid.org/0009-0001-2646-2364ГруздовАлександр Юрьевичalexander.gruzdov@inbox.ruКурский государственный медицинский университетРоссия2026020320261517283Copyright © Суковатых Б.С., Боломатов Н.В., Сидоров Д.В., Суковатых М.Б., Григорьян А.Ю., Груздов А.Ю., 20262026Суковатых Б.С., Боломатов Н.В., Сидоров Д.В., Суковатых М.Б., Григорьян А.Ю., Груздов А.Ю.Суковатых Б.С., Боломатов Н.В., Сидоров Д.В., Суковатых М.Б., Григорьян А.Ю., Груздов А.Ю.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/1679

В статье проанализированы данные отечественной и зарубежной литературы, раскрывающие проблему нарушений коронарного кровотока при эндоваскулярных вмешательствах. С современных позиций представлена роль различных факторов риска развития нарушения реперфузии миокарда. Описаны способы клинической и инструментальной диагностики феноменов замедленного и невосстановленного коронарного кровотока. Подчеркнута необходимость индивидуального подхода к применению лекарственных препаратов для купирования  коронарных нарушений. Акцентировано внимание на современных способах инструментальной профилактики холестериновой атероэмболии. Указано на необходимость исключения  рутинной тромбэктомии при чрескожных коронарных вмешательствах. 

чрескожное коронарное вмешательствохолестериновая атероэмболияфеномены замедленного и невосстановленного коронарного кровотокадиагностикапрофилактикалечениеReferencesOzkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag. 2019; 15: 209-220. doi: 10.2147/VHRM.S175150Ozkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag. 2019; 15: 209-220. doi: 10.2147/VHRM.S175150Pantea-Roșan L.R., Bungau S.G., Radu A.F., Pantea V.A., Moisi M.I., Vesa C.M., Behl T., Nechifor A.C., Babes E.E., Stoicescu M., Gitea D., Iovanovici D.C., Bustea C. A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon. Diagnostics (Basel). 2022; 12(4): 932. doi: 10.3390/diagnostics12040932Pantea-Roșan LR, Bungau SG, Radu AF, Pantea VA, Moisi MI, Vesa CM, Behl T, Nechifor AC, Babes EE, Stoicescu M, Gitea D, Iovanovici DC, Bustea C. A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon. Diagnostics (Basel). 2022; 12(4): 932. doi: 10.3390/diagnostics12040932Shahri B., Vojdanparast M. Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents. Razavi International Journal of Medicine. 2020; 8(1-4): e1002. doi: 10.30483/rijm.2020.254145.1002Shahri B, Vojdanparast M. Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents. Razavi International Journal of Medicine. 2020; 8(1-4): e1002. doi: 10.30483/rijm.2020.254145.1002Герасимов А.М., Терещенко А.С., Меркулов Е.В., Самко А.Н. Феномен невоcстановленного коронарного кровотока (no-reflow) в практике эндоваскулярного хирурга. Вестник рентгенологии и радиологии. 2014; (1): 51-55. doi: 10.20862/0042-4676-2014-0-1-51-55Gerasimov AM, Tereshchenko AS, Merkulov EV, Samko AN. No-reflow phenomenon in the practice of an endovascular surgeon. Journal of radiology and nuclear medicine. 2014;(1):51-55. (In Russ.) doi: 10.20862/0042-4676-2014-0-1-51-55Majno G., Ames A., Chaing J., Wright R.L. No reflow after cerebral ischemia. Lancet. 1967; 290(7515): 569-570. doi: 10.1016/S0140-6736(67)90552-1Majno G, Ames A, Chaing J, Wright RL. No reflow after cerebral ischemia. Lancet. 1967; 290(7515): 569-570. doi: 10.1016/S0140-6736(67)90552-1Халирахманов А.Ф., Газиев Э.А., Шарафеев А.З., Шарафутдинов Б.М. Развитие феномена «no-reflow» после чрескожных коронарных вмешательств: современные аспекты. Диагностическая и интервенционная радиология. 2019; 13(4): 57-66. doi: 10.25512/DIR.2019.13.4.06Khalirakhmanov AF, Gaziev EA, Sharafeev AZ, Sharafutdinov BM. Development of "no-reflow" phenomenon after percutaneous coronary interventions: current aspects. Diagnostic and Interventional Radiology. 2019; 13(4): 57-66. (In Russ) doi: 10.25512/DIR.2019.13.4.06Shah M., Mohsin M., Satti K.N. Predictors and in-hospital mortality of slow flow/no-reflow after percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Journal of Akhtar Saeed Medical & Dental College. 2023; 5(03): 144-151. doi: 10.51127/JAMDCV5I3OA05Shah M, Mohsin M, Satti KN. Predictors and in-hospital mortality of slow flow/no-reflow after percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Journal of Akhtar Saeed Medical & Dental College. 2023; 5(03): 144-151. doi: 10.51127/JAMDCV5I3OA05Avci E., Yildirim T., Aydin G., Kiris T., Dolapoglu A., Kadi H., Safak O., Bayata S. Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci. 2018; 22(15): 4987-4994. doi: 10.26355/eurrev_201808_15639Avci E, Yildirim T, Aydin G, Kiris T, Dolapoglu A, Kadi H, Safak O, Bayata S. Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci. 2018; 22(15): 4987-4994. doi: 10.26355/eurrev_201808_15639Savic L., Mrdovic I., Asanin M., Stankovic S., Lasica R., Krljanac G., Rajic D., Simic D. The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis. J Interv Cardiol. 2022; 2022: 5815274. doi: 10.1155/2022/5815274Savic L, Mrdovic I, Asanin M, Stankovic S, Lasica R, Krljanac G, Rajic D, Simic D. The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis. J Interv Cardiol. 2022; 2022: 5815274. doi: 10.1155/2022/5815274Kai T., Oka S., Hoshino K., Watanabe K., Nakamura J., Abe M., Watanabe A. Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0. Circ J. 2021; 85(10): 1770-1778. doi: 10.1253/circj.CJ-21-0221Kai T, Oka S, Hoshino K, Watanabe K, Nakamura J, Abe M, Watanabe A. Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0. Circ J. 2021; 85(10): 1770-1778. doi: 10.1253/circj.CJ-21-0221Hu X., Yang X., Li X., Li G., Zhou Y., Dong H. Elevated uric acid is related to the no-/slow-reflow phenomenon in STEMI undergoing primary PCI. Eur J Clin Invest. 2022; 52(4): e13719. doi: 10.1111/eci.13719Hu X, Yang X, Li X, Li G, Zhou Y, Dong H. Elevated uric acid is related to the no-/slow-reflow phenomenon in STEMI undergoing primary PCI. Eur J Clin Invest. 2022; 52(4): e13719. doi: 10.1111/eci.13719Somuncu M.U., Akgun T., Cakır M.O., Akgul F., Serbest N.G., Karakurt H., Can M., Demir A.R. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Atheroscler Thromb. 2019; 26(11): 970-978. doi: 10.5551/jat.48413Somuncu MU, Akgun T, Cakır MO, Akgul F, Serbest NG, Karakurt H, Can M, Demir AR. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Atheroscler Thromb. 2019; 26(11): 970-978. doi: 10.5551/jat.48413Zhang Q., Hu M., Ma S. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. J Atheroscler Thromb. 2021; 28(12): 1289-1297. doi: 10.5551/jat.59832Zhang Q, Hu M, Ma S. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. J Atheroscler Thromb. 2021; 28(12): 1289-1297. doi: 10.5551/jat.59832Sondergaard F.T., Beske R.P., Frydland M., Moller J.E., Helgestad O.K.L., Jensen L.O., Holmvang L., Goetze J.P., Engstrom T., Hassager C. Soluble ST2 in plasma is associated with post-procedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2023; 12(1): 48-52. doi: 10.1093/ehjacc/zuac146Sondergaard FT, Beske RP, Frydland M, Moller JE, Helgestad OKL, Jensen LO, Holmvang L, Goetze JP, Engstrom T, Hassager C. Soluble ST2 in plasma is associated with post-procedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2023; 12(1): 48-52. doi: 10.1093/ehjacc/zuac146Li Y., Liang X., Zhang W., Qiao X., Wang Z. The Clinical and Angiographic Outcomes of Postdilation after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Interv Cardiol. 2021; 2021: 6699812. doi: 10.1155/2021/6699812Li Y, Liang X, Zhang W, Qiao X, Wang Z. The Clinical and Angiographic Outcomes of Postdilation after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Interv Cardiol. 2021; 2021: 6699812. doi: 10.1155/2021/6699812Fajar J.K., Heriansyah T., Rohman M.S. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart J. 2018; 70(3): S406-S418. doi: 10.1016/j.ihj.2018.01.032Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart J. 2018; 70(3): S406-S418. doi: 10.1016/j.ihj.2018.01.032Gupta S., Gupta M.M. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016; 68(4): 539-51. doi: 10.1016/j.ihj.2016.04.006Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016; 68(4): 539-51. doi: 10.1016/j.ihj.2016.04.006Abtan J., Wiviott S.D., Sorbets E., Popovic B., Elbez Y., Mehta S.R., Sabatine M.S., Bode C., Pollack C.V., Cohen M., Moccetti T., Laanmets P., Faxon D., Okreglicki A., Ducrocq G., Steg P.G.; TAO investigators. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Arch Cardiovasc Dis. 2021; 114(3): 187-196. doi: 10.1016/j.acvd.2020.09.005Abtan J, Wiviott SD, Sorbets E, Popovic B, Elbez Y, Mehta SR, Sabatine MS, Bode C, Pollack CV, Cohen M, Moccetti T, Laanmets P, Faxon D, Okreglicki A, Ducrocq G, Steg PG; TAO investigators. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Arch Cardiovasc Dis. 2021; 114(3): 187-196. doi: 10.1016/j.acvd.2020.09.005Agrawal A., Ziccardi M.R., Witzke C., Palacios I., Rangaswami J. Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018; 31(3): 407-415. doi: 10.1111/joic.12483Agrawal A, Ziccardi MR, Witzke C, Palacios I, Rangaswami J. Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018; 31(3): 407-415. doi: 10.1111/joic.12483Alief W., Mukti C.N., Henry S. Cholesterol crystal embolism: Unraveling its impact on atherosclerotic cardiovascular diseases. Journal of Medicine, Surgery, and Public Health. 2024; 3: 100102. DOI: 10.1016/j.glmedi.2024.100102Alief W, Mukti CN, Henry S. Cholesterol crystal embolism: Unraveling its impact on atherosclerotic cardiovascular diseases. Journal of Medicine, Surgery, and Public Health. 2024; 3: 100102. DOI: 10.1016/j.glmedi.2024.100102Sinha S.K., Kumar P., Sharma A.K., Razi M., Pandey U., Sachan M., Shukla P., Aggarwal P., Jha M.J., Thakur R., Krishna V. Perforated balloon technique mediated intracoronary delivery of nicorandil to treat coronary no-reflow phenomenon: a novel pharmacological solution to precarious situation. Am J Cardiovasc Dis. 2021; 11(5): 544-554.Sinha SK, Kumar P, Sharma AK, Razi M, Pandey U, Sachan M, Shukla P, Aggarwal P, Jha MJ, Thakur R, Krishna V. Perforated balloon technique mediated intracoronary delivery of nicorandil to treat coronary no-reflow phenomenon: a novel pharmacological solution to precarious situation. Am J Cardiovasc Dis. 2021; 11(5): 544-554.Allencherril J., Jneid H., Atar D., Alam M., Levine G., Kloner R.A., Birnbaum Y. Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. Cardiovasc Drugs Ther. 2019; 33(5): 589-597. doi: 10.1007/s10557-019-06901-0Allencherril J, Jneid H, Atar D, Alam M, Levine G, Kloner RA, Birnbaum Y. Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. Cardiovasc Drugs Ther. 2019; 33(5): 589-597. doi: 10.1007/s10557-019-06901-0Hu X., Wang W., Ye J., Lin Y., Yu B., Zhou L., Zhou Y., Dong H. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon. Biomed Pharmacother. 2021; 143: 112196. doi: 10.1016/j.biopha.2021.112196Hu X, Wang W, Ye J, Lin Y, Yu B, Zhou L, Zhou Y, Dong H. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon. Biomed Pharmacother. 2021; 143: 112196. doi: 10.1016/j.biopha.2021.112196De Luca G., Suryapranata H., Stone G.W., Antoniucci D., Tcheng J.E., Neumann F.J., Van de Werf F., Antman E.M., Topol E.J. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005; 293(14): 1759-1765. doi: 10.1001/jama.293.14.1759De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005; 293(14): 1759-1765. doi: 10.1001/jama.293.14.1759Petronio A.S., Rovai D., Musumeci G., Baglini R., Nardi C., Limbruno U., Palagi C., Volterrani D., Mariani M. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J. 2003; 24(1): 67-76. doi: 10.1016/s0195-668x(02)00324-1Petronio AS, Rovai D, Musumeci G, Baglini R, Nardi C, Limbruno U, Palagi C, Volterrani D, Mariani M. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J. 2003; 24(1): 67-76. doi: 10.1016/s0195-668x(02)00324-1Simoons M.L., GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The Lancet. 2001; 357(9272): 1915-24. DOI: 10.1016/S0140-6736(00)05060-1Simoons ML; GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The Lancet. 2001; 357(9272): 1915-24. doi: 10.1016/S0140-6736(00)05060-1Сухинина Т.С., Певзнер Д.В., Мазуров А.В., Власик Т.Н., Соловьёва Н.Г., Кострица Н.С., Шахнович Р.М., Явелов И.С. Роль блокаторов гликопротеина IIb / IIIa рецепторов тромбоцитов при современном лечении больных с острым коронарным синдромом. Кардиология. 2022; 62(4): 64-72. doi: 10.18087/cardio.2022.4.n2020Sukhinina TS, Pevzner DV, Mazurov AV, Vlasik TN, Solovieva NG, Kostritca NS, Shakhnovich RM, Yavelov IS. The role of platelet glycoprotein IIb / IIIa inhibitors in current treatment of acute coronary syndrome. Kardiologiia. 2022; 62(4): 64-72. (In Russ) doi: 10.18087/cardio.2022.4.n2020Callichurn K., Simard P., De Marco C., Jamali P., Saada Y., Matteau A., Schampaert E., Mansour S., Hatem R., Potter B.J. A dual-center analysis of conservative versus liberal glycoprotein IIb-IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction. Sci Rep. 2024; 14(1): 15003. doi: 10.1038/s41598-024-64652-xCallichurn K, Simard P, De Marco C, Jamali P, Saada Y, Matteau A, Schampaert E, Mansour S, Hatem R, Potter BJ. A dual-center analysis of conservative versus liberal glycoprotein IIb-IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction. Sci Rep. 2024; 14(1): 15003. doi: 10.1038/s41598-024-64652-xBocchino P.P., Angelini F., Gallone G., Frea S., De Ferrari G.M. The cardiovascular safety of sodium nitroprusside in acute heart failure. Expert Opin Drug Saf. 2024; 23(6): 663-666. doi: 10.1080/14740338.2024.2348570Bocchino PP, Angelini F, Gallone G, Frea S, De Ferrari GM. The cardiovascular safety of sodium nitroprusside in acute heart failure. Expert Opin Drug Saf. 2024; 23(6): 663-666. doi: 10.1080/14740338.2024.2348570Berg R., Buhari C. Treating and preventing no reflow in the cardiac catheterization laboratory. Current cardiology reviews. 2012; 8(3): 209-214.Berg R, Buhari C. Treating and preventing no reflow in the cardiac catheterization laboratory. Current cardiology reviews. 2012; 8(3): 209-214.Procopio M.C., Lauro R., Nasso C., Carerj S., Squadrito F., Bitto A., Di Bella G., Micari A., Irrera N., Costa F. Role of Adenosine and Purinergic Receptors in Myocardial Infarction: Focus on Different Signal Transduction Pathways. Biomedicines. 2021; 9(2): 204. doi: 10.3390/biomedicines9020204Procopio MC, Lauro R, Nasso C, Carerj S, Squadrito F, Bitto A, Di Bella G, Micari A, Irrera N, Costa F. Role of Adenosine and Purinergic Receptors in Myocardial Infarction: Focus on Different Signal Transduction Pathways. Biomedicines. 2021; 9(2): 204. doi: 10.3390/biomedicines9020204Laborante R., Bianchini E., Restivo A., Ciliberti G., Galli M., Vergallo R., Rodolico D., Zito A., Princi G., Leone A.M., Aurigemma C., Romagnoli E., Montone R.A., Burzotta F., Trani C., Crea F., D'Amario D. Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023; 9(2): 173-182. doi: 10.1093/ehjcvp/pvac069Laborante R, Bianchini E, Restivo A, Ciliberti G, Galli M, Vergallo R, Rodolico D, Zito A, Princi G, Leone AM, Aurigemma C, Romagnoli E, Montone RA, Burzotta F, Trani C, Crea F, D'Amario D. Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023; 9(2): 173-182. doi: 10.1093/ehjcvp/pvac069Grancini L., Diana D., Centola A., Monizzi G., Mastrangelo A., Olivares P., Montorsi P., Alushi B., Bartorelli A.L., Galassi A.R. The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI. J Clin Med. 2023; 12(6): 2405. doi: 10.3390/jcm12062405Grancini L, Diana D, Centola A, Monizzi G, Mastrangelo A, Olivares P, Montorsi P, Alushi B, Bartorelli AL, Galassi AR. The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI. J Clin Med. 2023; 12(6): 2405. doi: 10.3390/jcm12062405Egred M., Bagnall A., Spyridopoulos I., Purcell I.F., Das R., Palmer N., Grech E.D., Jain A., Stone G.W., Nijveldt R., McAndrew T., Zaman A. Effect of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size in anterior STEMI: PiCSO in ACS study. Int J Cardiol Heart Vasc. 2020; 28: 100526. doi: 10.1016/j.ijcha.2020.100526Egred M, Bagnall A, Spyridopoulos I, Purcell IF, Das R, Palmer N, Grech ED, Jain A, Stone GW, Nijveldt R, McAndrew T, Zaman A. Effect of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size in anterior STEMI: PiCSO in ACS study. Int J Cardiol Heart Vasc. 2020; 28: 100526. doi: 10.1016/j.ijcha.2020.100526Gibson C.M., Ajmi I., von Koenig C.L., Turco M.A., Stone G.W. Pressure-Controlled Intermittent Coronary Sinus Occlusion: A Novel Approach to Improve Microvascular Flow and Reduce Infarct Size in STEMI. Cardiovasc Revasc Med. 2022; 45: 9-14. doi: 10.1016/j.carrev.2022.07.007Gibson CM, Ajmi I, von Koenig CL, Turco MA, Stone GW. Pressure-Controlled Intermittent Coronary Sinus Occlusion: A Novel Approach to Improve Microvascular Flow and Reduce Infarct Size in STEMI. Cardiovasc Revasc Med. 2022; 45: 9-14. doi: 10.1016/j.carrev.2022.07.007Texakalidis P., Letsos A., Kokkinidis D.G., Schizas D., Karaolanis G., Giannopoulos S., Giannopoulos S., Economopoulos K.P., Bakoyannis C. Proximal embolic protection versus distal filter protection versus combined protection in carotid artery stenting: A systematic review and meta-analysis. Cardiovasc Revasc Med. 2018; 19(5 Pt A): 545-552. doi: 10.1016/j.carrev.2017.12.010Texakalidis P, Letsos A, Kokkinidis DG, Schizas D, Karaolanis G, Giannopoulos S, Giannopoulos S, Economopoulos KP, Bakoyannis C. Proximal embolic protection versus distal filter protection versus combined protection in carotid artery stenting: A systematic review and meta-analysis. Cardiovasc Revasc Med. 2018; 19(5 Pt A): 545-552. doi: 10.1016/j.carrev.2017.12.010Giannopoulos S., Sagris M., Giannopoulos S., Tzoumas A., Kokkinidis D.G., Texakalidis P., Koutsias G., Volteas P., Jing L., Malgor R.D. Embolic protection devices for carotid artery stenting: A network meta-analysis. Vascular. 2024; 32(2): 447-457. doi: 10.1177/17085381221140616Giannopoulos S, Sagris M, Giannopoulos S, Tzoumas A, Kokkinidis DG, Texakalidis P, Koutsias G, Volteas P, Jing L, Malgor RD. Embolic protection devices for carotid artery stenting: A network meta-analysis. Vascular. 2024; 32(2): 447-457. doi: 10.1177/17085381221140616Celik M., Yuksel U.C., Yalcinkaya E., Gokoglan Y., Iyisoy A. Conservative treatment of iatrogenic left main coronary artery dissection: report of two cases. Cardiovasc Diagn Ther. 2013; 3(4): 244-246. doi: 10.3978/j.issn.2223-3652.2013.10.04Celik M, Yuksel UC, Yalcinkaya E, Gokoglan Y, Iyisoy A. Conservative treatment of iatrogenic left main coronary artery dissection: report of two cases. Cardiovasc Diagn Ther. 2013; 3(4): 244-246. doi: 10.3978/j.issn.2223-3652.2013.10.04De Luca L., Sardella G., Davidson C.J., De Persio G., Beraldi M., Tommasone T., Mancone M., Nguyen B.L., Agati L., Gheorghiade M., Fedele F. Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction. Heart. 2006; 92(7): 951-957. doi: 10.1136/hrt.2005.074716De Luca L, Sardella G, Davidson CJ, De Persio G, Beraldi M, Tommasone T, Mancone M, Nguyen BL, Agati L, Gheorghiade M, Fedele F. Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction. Heart. 2006; 92(7): 951-957. doi: 10.1136/hrt.2005.074716Satti Z., Omari M., Bawamia B., Cartlidge T., Egred M., Farag M., Alkhalil M. The Use of Thrombectomy during Primary Percutaneous Coronary Intervention: Resurrecting an Old Concept in Contemporary Practice. J Clin Med. 2024; 13(8): 2291. doi: 10.3390/jcm13082291Satti Z, Omari M, Bawamia B, Cartlidge T, Egred M, Farag M, Alkhalil M. The Use of Thrombectomy during Primary Percutaneous Coronary Intervention: Resurrecting an Old Concept in Contemporary Practice. J Clin Med. 2024; 13(8): 2291. doi: 10.3390/jcm13082291Zhou L., Hu X., Zhang H., Lu H., Lin Y., Wang W., Yu B., Liang W., Zhou Y., Li G., Dong H. Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction. J Int Med Res. 2023; 51(6): 3000605231182547. doi: 10.1177/03000605231182547Zhou L, Hu X, Zhang H, Lu H, Lin Y, Wang W, Yu B, Liang W, Zhou Y, Li G, Dong H. Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction. J Int Med Res. 2023; 51(6): 3000605231182547. doi: 10.1177/03000605231182547Михайлова З.Д., Климкин П.Ф. Синдром холестериновой атероэмболии: современное состояние проблемы. Архивъ внутренней медицины. 2020; 10(4): 272-280. doi: 10.20514/2226-6704-2020-10-4-272-280Mikhailova ZD, Klimkin PF. Cholesterol Atheroembolism Syndrome: Current State of the Problem. The Russian Archives of Internal Medicine. 2020; 10(4): 272-280. (In Russ) doi: 10.20514/2226-6704-2020-10-4-272-280

The authors declare that there are no conflicts of interest present.